The risk for asynchronous contralateral breast cancer is two to six times greater than the risk for a first primary breast cancer in the general population of women ( 1 ). In a recent update by the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) ( 2 ), which included 194 randomized treatment trials, adjuvant chemotherapy was compared with no chemotherapy. Women who were younger than 50 years when treated with chemotherapy had reduced risk of developing contralateral breast cancer (HR = 0.66; P = .003), whereas no effect was observed among women 50 years and older. The EBCTCG overview also showed that administration of tamoxifen for a median of 5 years vs no tamoxifen reduced the risk for contralateral breast cancer among women who originally had
estrogen receptor (ER)-positive or ER-unknown disease (HR = 0.61; P < .001), whereas there was no impact on women who originally had ER-poor disease ( 2 , 3 ) . Overall risk reductions of 30% -80% for contralateral breast cancer have been reported in observational studies of women treated for breast cancer with chemotherapy ( 4 -7 ) and studies of women treated with tamoxifen ( 8 -9 ) . Cytostatic drugs are believed to work by eradicating unrecognized microscopic tumors and inducing menopause in premenopausal women ( 10 ) . Tamoxifen, a selective ER modulator, exerts an antiestrogenic effect on breast tissue by binding to ERs, thus delaying or hampering the development of a new breast cancer ( 11 ) .
Although chemotherapy and tamoxifen seem to act independently to protect against the development of contralateral breast cancer, little is known about the duration of benefi cial effects, whether they vary by host-and tumor-related factors ( 6 , 12 ) , and whether the therapeutic benefi t is due to the induction of early menopause. With particular emphasis on these issues, we investigated the association between chemotherapy and tamoxifen and the risk for contralateral breast cancer among women who were diagnosed with a fi rst breast cancer when they were younger than age 55 and who participated in the multicenter Women's Environment, Cancer and Radiation Epidemiology (WECARE) Study ( 13 ) .
Subjects and Methods

Study Population
Women with contralateral breast cancer (case patients) and women with unilateral breast cancer (control subjects) were recruited to participate in the WECARE Study ( 13 ) All fi rst primary breast cancers were invasive without distant metastases and were diagnosed between January 1, 1985, and December 31, 1999 , in women aged 54 years or younger at diagnosis. Case patients were eligible for the study if a second primary breast cancer (invasive or in situ) was diagnosed at least 12 months after the initial diagnosis. Case patients were required to have resided in the same reporting area at the time of diagnosis of both cancers and to have had no prior or intervening cancer diagnosis between their fi rst and second primary breast cancers. The second primary breast cancer had to have been diagnosed no later than December 31, 2001 . Control subjects had no contralateral breast cancer during the interval between the matched case patient's fi rst and second breast cancers ("at-risk" period), had no prophylactic mastectomy during the at-risk period, and had no prior or intervening cancer diagnoses. The reference date for case patients was the date of diagnosis of the second primary breast cancer and that for control subjects was defi ned by adding the at-risk period for the matched case patient to the date of diagnosis for the primary breast cancer for the control subject. All women had to be alive at the time of interview. Two control subjects were individually matched to each woman with contralateral breast cancer on year of birth (in 5-year strata), year of diagnosis (in 4-year strata), registry region, and race and were counter matched on radiotherapy (yes or no). As implemented in the WECARE Study, the counter-matching design specifi es that each case -control set consists of two women who had received radiotherapy based on cancer registry records and one woman who had not; that is, control subjects are sampled from the pool of eligible control subjects so that the case -control set will have this structure ( 13 , 14 ) . Counter matching was used to improve the statistical effi ciency of the main study, which was designed to assess whether genetic factors involved in DNA repair, in combination with radiation exposure, were associated with an increased risk for contralateral breast cancer ( 13 ) . Sampling weights were calculated to account for the sampling probability of counter matching.
Medical records were retrieved to obtain detailed information on the treatment of the fi rst breast cancer (chemotherapy, hormonal therapy, and radiotherapy) during the at-risk period. The information on chemotherapy and hormonal therapy included dates of administration, reason for treatment (primary disease, recurrence, other, or unknown), and type of drug. The two standard chemotherapy regimens most commonly used during the study period were based on cyclophosphamide, methotrexate, and 5-fl uorouracil (CMF) and on cyclophosphamide, epirubicin/adriamycin, and 5-fl uorouracil (CEF/CAF). The remaining chemotherapy regimens were categorized as either "other anthracycline-based regimens"
CONTEXT AND CAVEATS
Prior knowledge
Breast cancer patients who are treated with tamoxifen or chemotherapy have a reduced risk for contralateral breast cancer.
Study design
Case -control study of women 54 years of age and younger with contralateral or unilateral nonmetastatic invasive breast cancer who were treated with tamoxifen, chemotherapy, radiotherapy, or surgery alone.
Contributions
Chemotherapy was associated with a reduced risk for contralateral breast cancer that continued 10 years after diagnosis. The association was stronger among women who became postmenopausal within 1 year of their first breast cancer diagnosis. Tamoxifen treatment was associated with a reduced risk for contralateral breast cancer that continued for 5 years after diagnosis.
Implications
Ovarian suppression may be involved in the association between reduced risk for contralateral breast cancer and chemotherapy.
Limitations
Although the study was restricted to nonmetastatic breast cancer, it is possible that metastases were classified as new primary breast cancers. Findings were based solely on breast cancer survivors; thus, the potential for survivor bias exists and the findings may not apply to all breast cancer patients. No adjustments for oophorectomy or ovarian radiation were performed.
or "other." The characteristics of the fi rst breast tumors were extracted from tumor registry records, and further data were obtained from hospital and physician medical records.
Participants were interviewed by telephone with a structured questionnaire to obtain information on known breast cancer risk factors, such as family history of breast cancer, reproductive history, use of hormones, alcohol intake, and body mass index (BMI). In addition, for the subset of women for whom information from medical records on chemotherapy and/or hormonal therapy was missing, the information was obtained during the telephone interview with the participant. All participants provided written informed consent before enrollment into the WECARE Study, and the research protocol was approved by the respective institutional review boards and by the ethical committee system in Denmark.
Of the 998 case patients and 2112 control subjects who were eligible and approached for agreement to participate in the study, 708 (71%) case patients and 1399 (66%) control subjects were enrolled. Most (79%) of the second primary tumors of the enrolled case patients were invasive.
We then excluded women who had been treated with chemotherapy and/or hormonal therapy for a recurrence of their fi rst primary breast cancer and women with missing information on covariates used in the statistical models. Women who were treated for a recurrence were identifi ed based on medical record information; if the reason for treatment was unknown, women were considered to have been treated for a recurrence if systemic treatment was initiated more than 1 year after the primary diagnosis of breast cancer. In total, we excluded 191 women treated for a recurrence (59 case patients and 132 control subjects): 57 women treated with chemotherapy, 105 women who received hormonal therapy, and 29 women who received both chemotherapy and hormonal therapy. We further excluded six women (two case patients and four control subjects) with missing information on potential confounders (see below). All these exclusions further resulted in the elimination of 13 case patients for whom all control subjects were excluded and 105 control subjects (17 single control subjects and 44 pairs of control subjects). The fi nal study population therefore consisted of 1792 subjects (634 case patients with contralateral breast cancer and 1158 control subjects with unilateral breast cancer, including 524 triplets [one case patient, two control subjects] and 110 pairs [one case patient, one control subject]). As already mentioned, when information on chemotherapy and/or hormonal therapy was missing in the medical record, this information was obtained during the telephone interview. After the exclusions, 4% of all subjects had information on chemotherapy from the interview and 0.1% of all subjects had information on tamoxifen use from the interview.
Statistical Methods
Rate ratios (RRs) and corresponding 95% confidence intervals (CIs) were estimated by multivariable conditional logistic regression models using the TPHREG procedure in SAS release 9.1 (SAS Institute, Inc., Cary, NC), which accounted for the counter-matched design by including weights as an "offset" term in the model ( 13 , 14 ) . In the initial analyses, rate ratios were calculated for women who received chemotherapy only, tamoxifen only, or combinations of treatment, with women who had undergone surgery only as the referent group. In addition, the effects of chemotherapy and tamoxifen were estimated separately by fitting univariate and multivariable conditional logistic regression models that included women who had never received chemotherapy or hormonal therapy, respectively, as the referent groups. In the latter models, we investigated the impact of chemotherapy and tamoxifen treatment on the risk for contralateral breast cancer by intervals of time since diagnosis of the first breast cancer (1 -5, >5 to 10, or >10 years) and by host and tumor characteristics ( . We tested for statistical heterogeneity of treatment effects on risk for contralateral breast cancer across strata of these characteristics. The effect of different chemotherapy regimens was also assessed. Tamoxifen may have a considerable carry-over benefit that lasts some years after termination of the treatment ( 16 ) . Therefore, we investigated impact of duration of tamoxifen use and time since last use of tamoxifen among women with more than 10 years between the first breast cancer diagnosis and the reference date. Finally, we explored whether an interaction between use of tamoxifen and chemotherapy was present.
In the multivariable analyses, we included exact age at diagnosis of the fi rst primary breast cancer (continuous), family history of breast cancer among fi rst-degree relatives (yes, no, or adopted), lobular histology of the fi rst breast cancer (yes or no), and stage of fi rst breast cancer (local or regional). The analyses for the effect of chemotherapy included terms for radiotherapy (yes or no) and hormonal therapy (yes or no). The analyses examining the effect of tamoxifen included terms for radiotherapy (yes or no), chemotherapy (yes or no), and other hormonal therapy than tamoxifen (yes or no). All statistical tests were two-sided; P values less than .05 were considered as statistically signifi cant.
Results
The distribution of case patients and control subjects by study center, exposure to radiotherapy (yes or no), and the extent of the first breast cancer diagnosis is shown separately for all 2107 women who participated in the WECARE Study and for the 1792 women eligible for the present analysis ( Table 1 ). The relative risk for contralateral breast cancer among women who were excluded in this study because they had been treated with chemotherapy and/or hormonal therapy for a recurrence compared with women who had not been treated for a recurrence was 0.76 (95% CI = 0.52 to 1.11) (data not shown in tables). The median age at diagnosis of a first breast cancer of the women included in this study was 46 years (range = 23 -54 years). The median interval between first breast cancer and the reference date was 4 years (range = 1 -16 years).
In the initial analyses, women who had undergone surgery as the only breast cancer treatment were used as the referent group ( Table 2 ) . Chemotherapy was the only adjuvant treatment used for 92 (15%) of the case patients and 86 (7%) of the control subjects, and a reduced risk for contralateral breast cancer was associated with chemotherapy only (RR = 0.53, 95% CI = 0.34 to 0.83). Tamoxifen was the only adjuvant therapy used for 36 (6%) of the case patients and 20 (2%) of the control subjects. No association between the risk for contralateral breast cancer and tamoxifen use only was observed (RR = 0.99, 95% CI = 0.50 to 1.97). The combination of tamoxifen and chemotherapy was received by 36 (6%) of the case patients and 116 (10%) of the control subjects and was associated with a decreased risk for contralateral breast cancer (RR = 0.43, 95% CI = 0.23 to 0.80).
The interaction between tamoxifen and chemotherapy was explored in another model in which the combination of no use of tamoxifen and no use of chemotherapy was the referent group. In this model, the combinations of no tamoxifen and use of chemotherapy (RR = 0.59, 95% CI = 0.43 to 0.82) and receiving both tamoxifen and chemotherapy (RR = 0.36, 95% CI = 0.23 to 0.56) were associated with a reduced risk for contralateral breast cancer; for the combination of tamoxifen use and no chemotherapy, an association was suggested (RR = 0.74, 95% CI = 0.50 to 1.08). The P value was .43 for the interaction between tamoxifen and chemotherapy.
Women who had received chemotherapy had a lower overall risk for contralateral breast cancer than those who had never received chemotherapy (RR = 0.57, 95% CI = 0.42 to 0.75) ( Table 3 ) . Although the tests for heterogeneity of the risk estimates did not reach statistical signifi cance, the association with chemotherapy appeared to be modifi ed by time since and age at fi rst diagnosis, menopausal status 1 year after the fi rst diagnosis, and BMI. The association with chemotherapy was statistically signifi cant both when the time since diagnosis of the fi rst breast cancer was 1 -5 years (RR = 0.61, 95% CI = 0.44 to 0.86) and when it was >5 to 10 years (RR = 0.43, 95% CI = 0.27 to 0.68), whereas the risk was close to unity more than 10 years after the fi rst breast cancer diagnosis (RR = 0.98, 95% CI = 0.41 to 2.35). Highly Table 1 * RR = rate ratio; CI = confidence interval. † Treatment categories are mutually exclusive. All categories include surgery. ‡ Includes women who had hormonal therapy other than tamoxifen (six case patients and seven control subjects). These were analyzed in a separate group (not shown). § Adjusted for counter-matching sampling, exact age at first primary breast cancer (continuous), family history of breast cancer among first-degree relatives (yes, no, or adopted), lobular histology of first primary breast cancer (yes or no), and stage of first primary breast cancer (local or regional).
statistically signifi cant reductions in the risk for contralateral breast cancer were seen for women who were 45 -49 years of age at the time of fi rst diagnosis (RR = 0.42, 95% CI = 0.27 to 0.66) and for women who became postmenopausal within the fi rst year after the primary diagnosis and breast cancer treatment (RR = 0.28, 95% CI = 0.11 to 0.76). The association of reduced risk with chemotherapy varied somewhat by BMI at the time of diagnosis of the fi rst breast cancer ( Table 3 ) . When the subgroups of women with BMI less than 30 kg/m 2 were combined, chemotherapy was associated with a statistically signifi cantly reduced risk for contralateral breast cancer (RR = 0.54, 95% CI = 0.40 to 0.72), whereas there was no association among women whose BMI was 30 kg/m 2 or greater at the time of diagnosis (RR = 0.89, 95% CI = 0.48 to 1.65) ( P = .09 for test for heterogeneity) (categories different from those shown in Table 3 ). No variations in association between chemotherapy and the risk for contralateral breast cancer by other host and tumor characteristics were noted ( Table 3 ). The association of chemotherapy and reduced contralateral breast cancer risk did not vary statistically signifi cantly among the major chemotherapy regimens, for example, CMF or CEF/CAF, although no association with other anthracycline-based regimens was evident (RR = 0.90, 95% CI = 0.55 to 1.49) ( Table 4 ) .
Of the 502 breast cancer patients who had received hormonal therapy for their fi rst breast cancer, 489 had received tamoxifen and 13 had received aromatase inhibitors, other selective ER modulators, testosterone, or progesterone. The median duration of tamoxifen use among the 383 women with known duration was 2.7 years (5th percentile = 3 months, 95th percentile = 6.8 years), and the time since last use was 1.9 months (5th percentile = 0, 95th percentile = 5.6 years). The overall risk for contralateral breast cancer among women who had been treated with tamoxifen was reduced compared with that in women who had not received * RR = rate ratio; CI = confidence interval; BMI = body mass index; ER = estrogen receptor. † RRs are adjusted for the counter-matching sampling and for the following covariates: exact age at first primary breast cancer (continuous), family history of breast cancer among first-degree relatives (yes, no, or adopted), lobular histology of first primary breast cancer (yes or no), stage of first primary breast cancer (local or regional), radiotherapy (yes or no), and hormonal therapy (yes or no). ‡ P for statistical heterogeneity (two-sided) using likelihood ratio test. § RRs are adjusted for all covariates listed above except for age at first diagnosis.
|| One case patient and six control subjects had unknown menopausal status and were analyzed in a separate group (not shown). ¶ RRs are adjusted for all covariates listed above except for family history of breast cancer; 11 case patients and 23 control subjects were adopted and analyzed in a separate group (not shown).
# RRs are adjusted for all covariates listed above except for histology of first primary tumor.
tamoxifen (RR = 0.66, 95% CI = 0.50 to 0.88) ( Table 5 ). Tamoxifen use was associated with a statistically signifi cantly decreased risk for contralateral breast cancer only when the time since fi rst breast cancer diagnosis was limited to 5 years (RR = 0.55, 95% CI = 0.39 to 0.78), although a decreased risk was suggested in the >5-to-10-year interval (RR = 0.74, 95% CI = 0.43 to 1.28). Women who were treated with tamoxifen and were followed-up for more than 10 years after diagnosis of a fi rst breast cancer had an increased risk for contralateral breast cancer (RR = 3.84, 95% CI = 1.11 to 13.3).
Although the test for heterogeneity of the risk estimates did not reach statistical signifi cance, the association of reduced risk of contralateral breast cancer with tamoxifen appeared to be modifi ed by age, with the most marked decrease seen among women younger than 45 years (RR = 0.49, 95% CI = 0.30 to 0.82). Among women whose fi rst breast cancer was ER-positive, tamoxifen treatment was associated with a statistically signifi cantly reduced risk of contralateral breast cancer (RR = 0.60, 95% CI = 0.42 to 0.85). No clear effects of the other host and tumor characteristics were seen on the risk for contralateral breast cancer risk associated with tamoxifen treatment. Women who were diagnosed with their fi rst breast cancer more than 10 years before the reference date used tamoxifen for a median of 4.8 years (5th percentile = 6 months, 95th percentile = 9.2 years), and the median time since last use was 4.9 years (5th percentile = 1 day, 95th percentile = 11.4 years). Among these women, the RR was 0.80 (95% CI = 0.66 to 0.98) for each 6-month increase in duration of tamoxifen use ( P trend = .03), and the RR was 1.15 (95% CI = 0.97 to 1.35) for each 6-month increase in time since last use ( P trend = .10; data not shown).
Because the results could potentially differ between US and Danish women, we performed a sensitivity analysis in which we excluded the 509 Danish subjects (173 case patients and 336 control subjects). The overall associations of contralateral breast cancer risk with chemotherapy (RR = 0.57, 95% CI = 0.40 to 0.81) and tamoxifen treatment (RR = 0.65, 95% CI = 0.48 to 0.89) for US subjects alone were similar to those of US and Danish subjects combined.
Discussion
We found that the risk for contralateral breast cancer was reduced by 35% -40% in women who were first diagnosed with breast cancer when they were younger than 55 years if they were treated with either chemotherapy or tamoxifen, compared with women who had never received such treatment. The inverse association between contralateral breast cancer risk and chemotherapy appeared to persist for as long as 10 years, whereas that with tamoxifen use appeared to be shorter. The association with chemotherapy was stronger among women who became postmenopausal within 1 year of the first diagnosis and weaker among obese women than nonobese women.
Some previous observational studies reported a 30% -70% reduction in the risk for contralateral breast cancer after chemotherapy ( 4 -7 ), whereas other studies reported no effect ( 9 , 17 ) . In none of these studies was risk by time since diagnosis of the fi rst breast cancer addressed, perhaps because most of the studies had low statistical power for assessing long-term risks. Our fi nding of no indication of a reduced risk 10 or more years after diagnosis of the fi rst breast cancer suggests a diminution of the inverse association between chemotherapy and the risk for contralateral breast cancer, but the data were limited by small numbers. The main effect of chemotherapy could be the eradication of small breast cancer foci in the contralateral breast; however, the low risk of contralateral breast cancer observed among women who became postmenopausal within 1 year after the fi rst breast cancer diagnosis suggests that an endocrine effect of chemotherapy by induction of ovarian failure also contributes to reduce the risk of contralateral breast cancer. The endocrine effect would also be expected to diminish over time due to the occurrence of natural menopause among those not receiving chemotherapy. Furthermore, the EBCTCG overview ( 2 , 3 ) showed that chemotherapy had a protective effect on contralateral breast cancer only among women younger than 50 years, that is, among women who may experience chemotherapy-induced premature menopause. A weaker association between contralateral breast cancer risk and chemotherapy among women with a higher BMI was suggested by one casecontrol study ( 6 ) and by our results. Several explanations for the attenuation of the association have been proposed, including that the dose of chemotherapy for obese breast cancer patients is systematically reduced to avoid toxic reactions ( 18 ) , that the probability of amenorrhea associated with chemotherapy is reduced in premenopausal obese breast cancer patients, and that, if menopause is induced, the estrogen production in peripheral adipose tissue counteracts the benefi cial effects of menopause ( 19 ) .
The reduction in the risk for contralateral breast cancer associated with tamoxifen use compared with no use observed in our study is compatible with the previous observational studies ( 8 -9 ) . Although we saw no reduced risk of contralateral breast cancer among women receiving tamoxifen alone compared with women who had undergone surgery, indicating that tamoxifen must be supplemented by chemotherapy for the association to occur, this fi nding of no association between tamoxifen use alone and * RR = rate ratio; CI = confidence interval; C = cyclophosphamide; M = methotrexate; F = 5-fluorouracil; E = epirubicin; A = adriamycin. † Seven case patients and 12 control subjects on unknown regimen were analyzed in a separate group (not shown). ‡ Adjusted for counter-matching sampling, exact age at first primary breast cancer (continuous), family history of breast cancer among first-degree relatives (yes, no, or adopted), lobular histology of first primary breast cancer (yes or no), stage of first primary breast cancer (local or regional), radiotherapy (yes or no), and hormonal therapy (yes or no). § P (two-sided) for whether the model including estimates for each single regimen could be replaced by the model including an estimate for chemotherapy (yes or no) using likelihood ratio test.
contralateral breast cancer should be interpreted with caution. First, the number of women who received tamoxifen only (36 case patients and 20 control subjects) was small, and the confi dence intervals for this fi nding were wide; thus, a risk reduction as low as 50% cannot be rejected. Second, we found no statistically significant interaction between treatment with chemotherapy and tamoxifen. Finally, use of tamoxifen without chemotherapy was associated with reduced risk for contralateral breast cancer in three previous studies ( 17 , 20 , 21 ) , although in two of the studies the reduction was not statistically signifi cant ( 17 , 20 ) . To our knowledge, no observational studies have investigated the effect of tamoxifen on contralateral breast cancer by time since diagnosis of the fi rst breast cancer, and the clinical studies of late effects of tamoxifen focused on recurrence and mortality. There is no indication so far from the randomized International Breast Cancer Intervention Study Trial ( 22 ) , the Royal Marsden Trial ( 23 ), or the National Surgical Adjuvant and Bowel Project Breast Cancer Prevention Trial (P-1) Study ( 24 ) that the prophylactic effect of tamoxifen treatment among high-risk women diminishes over time. However, in these studies, women treated with tamoxifen had no previous breast cancer, the outcome was a fi rst primary breast cancer, and duration of tamoxifen treatment was standardized to 5 or 8 years, that is, settings differed from those of our study. The increased risk for contralateral breast cancer that we observed 10 years after the fi rst breast cancer among tamoxifen users compared with nonusers should be interpreted cautiously because it is based on relatively few women. Although the concordance in ER status between a fi rst and a second breast cancer is uncertain ( 25 , 26 ) , it has been shown that tamoxifen has the most favorable effect on contralateral breast cancer risk when the fi rst * RR = rate ratio; CI = confidence interval; BMI = body mass index; ER = estrogen receptor. † RRs are adjusted for the counter-matching sampling and for the following covariates: exact age at first primary breast cancer (continuous), family history of breast cancer among first-degree relatives (yes, no, or adopted), lobular histology of first primary breast cancer (yes or no), stage of first primary breast cancer (local or regional), radiotherapy (yes or no), chemotherapy (yes or no), and other hormonal therapy (yes or no). ‡ P for statistical heterogeneity (two-sided) using likelihood ratio test. § RRs are adjusted for all covariates above, except exact age at first diagnosis.
|| One case patient and six control subjects had unknown menopause and were analyzed in a separate group (not shown). ¶ RRs are adjusted for all covariates listed above except family history of breast cancer; 11 case patients and 23 control subjects were adopted and analyzed in a separate group (not shown).
# RRs are adjusted for all covariates listed above, except histology of the first primary tumor.
breast cancer is ER-positive ( 2 , 20 ) , which is consistent with our fi ndings. Based on results for women with more than 10 years between the fi rst primary breast cancer and the reference date, it appeared that a longer duration of tamoxifen use is associated with a lower risk for contralateral breast cancer than a shorter duration.
Evidence from previous studies also suggests that longer treatment times with tamoxifen are more effective in preventing contralateral breast cancer than shorter treatment times ( 8 , 27 , 28 ) . Overall, our observations suggest that tamoxifen users experience a reduced rate of contralateral breast cancers but raise questions as to how long the association persists. Although we restricted this study to women diagnosed with localized or regional disease and specifi ed a minimum of 1 year between the fi rst and second breast cancer, the possibility that metastases were misclassifi ed as new primary breast cancers remains. However, recent studies that have compared pairs of fi rst primary and contralateral breast tumors from the same patients using molecular profi ling suggest that most diagnosed contralateral breast cancers are independent occurrences of the disease ( 29 -31 ) . All case patients and control subjects had to be alive at date of interview, so our fi ndings are based on breast cancer survivors, and we cannot rule out the potential for a survival bias in our results. The restriction to survivors also means that the results might not apply to all breast cancer patients. Finally, we were not able to control for potential confounding of bilateral oophorectomy and ovarian radiation.
The strengths of our study include its large sample size, the population-based approach, and detailed abstraction of medical records to confi rm the cancer-free interval for control subjects and to document the treatment history of both case patients and control subjects.
In summary, our results suggest that a substantial reduction in the risk for contralateral breast cancer is associated with chemotherapy and tamoxifen treatment among breast cancer patients diagnosed when they were younger than 55 years and that the reduction may last for up to 10 years after initial breast cancer diagnosis. Ovarian suppression caused by chemotherapy may have a role in the association, possibly in combination with a cytotoxic effect on prevalent subclinical contralateral breast cancers.
